QCI INTERPRET FOR ONCOLOGY
QCI Interpret for Oncology
FASTQ to final report: Ultra-fast workflow for CGP
As our molecular knowledge of cancer continually evolves, a new era in cancer care is...
QCI Interpret for Oncology
50 to 500 genes: Scale-up to comprehensive genomic profiling
In this webinar, we present a workflow-agnostic, informatics software solution that...
QCI Interpret for Oncology
Comparison of methods in routine somatic diagnostics
Dr. Mattia Schmid from UniLabs, Switzerland compares the methods of molecular oncology...
QCI Interpret for Oncology
Rapid, evidence-based reporting of oncology NGS tests at scale
Competing to offer a comprehensive genomic profiling service for solid or hematology...
QCI Interpret for Oncology
Gaining insights with transcriptomic profiling and mechanistic modeling
In this webinar, Moritz Schütte, head of next-generation sequencing data analysis at...
QCI Interpret for Oncology
Generate oncologist-ready clinical reports from comprehensive panels
Ruth Burton, Ph.D., Clinical Application Specialist, QIAGEN Digital Insights explains...
QCI Interpret for Oncology
Confidence and trust: Deliver valuable clinical insights with high-quality...
Ben Turner, Director of Bioinformatics Enterprise Solutions, QIAGEN Digital Insights...
QCI Interpret for Oncology
Going beyond: Molecular evidence for off-label therapy use
Kathryn Bungartz, Ph.D., Associate StaffField Application Scientist, QIAGEN Digital...
QCI Interpret for Oncology
Expert insights to advance NGS oncology profiling
Recently, GenomeWeb and Qiagen partnered on a survey that allowed participants to...
QCI Interpret for Oncology
QCI Interpret One: Oncology variant interpretation just got more precise
Competing to offer a comprehensive genomic profiling service for solid or hematology...
QCI Interpret for Oncology
Reduce your test turnaround for large cancer panels
Speaker: Sheryl Elkin, CSO, QDI, QIAGEN Interested in learning more? Click here
QCI Interpret for Oncology
Managing multiple biomarker therapeutic development
For the past two decades, the paradigm in the field has been “one biomarker, one drug,”...